



ProstaLund´s CoreTherm® can now be offered as a treatment in the Norwegian public healthcare system

“Beslutningsforum” for “Nye Metoder” in Norway decided on Monday that Transurethral Microwave Therapy (TUMT) can be offered as an alternative treatment for benign prostate hyperplasia.

In June, “Bestillerforum” in “Nye Metoder” in Norway decided to let the four regional “helseforetaker” decide whether CoreTherm® (TUMT) should be implemented as a method for the treatment of benign prostate enlargement in public healthcare. On Monday, it was decided that CoreTherm® can be offered as a treatment for benign prostate enlargement.

«Nye Metoder» is a system in Norway based on close cooperation between «spesialisthelsetjenesten ved de regionale helseforetakene, helseforetakene (sykehusene), Statens Legemiddelverk, Folkehelseinstituttet, Statens Strålevern og Helsedirektoratet.» A key task of «Nye Metoder» is to evaluate the efficacy, safety and cost-effectiveness of new treatments while comparing with existing ones. The evaluations form an important part of the knowledge base for decisions on the possible introduction or phasing out of methods in public healthcare in Norway.

“Beslutningsforum” minutes of the meeting of monday: «Beslutningen som er fattet av Beslutningsforum for nye metoder er resultat av en lang prosess og en grundig vurdering av de menneskelige konsekvenser som følger både av beslutning om innføring så vel som beslutning om ikke å innføre en metode forutredning, behandling og/eller prosedyre/organisering.» – «Transuretral mikrobølgebehandling (TUMT) kan tilbys som et alternativ ved behandling av benign prostatahyperplasi.»

CEO Johan Wennerholm comments:

"As the Beslutningsforum itself notes, it has been a long process but now there are no longer any barriers for hospitals to start up CoreTherm treatments if they and patients so wish. Today, CoreTherm is only performed at a private clinic in Oslo. Now the foundation is in place to ensure that more patients are offered CoreTherm® in Norway."

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
01 September 2021 09:15:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

ProstaLund's CoreTherm® can now be offered as a treatment in the Norwegian public healthcare system